What is better than nattokinase?

Search "what is better than nattokinase" and you'll find confident answers pointing to serrapeptase, lumbrokinase, or fish oil — but "better" is the wrong question until you ask "better at what?"

Nattokinase carries a deeper human clinical record than most of its rivals: at least six randomized trials and 546 participants in one 2023 meta-analysis alone. The smarter question is which option actually fits your specific goal.

Table of Contents

• 1. What Nattokinase Actually Does
• 2. Serrapeptase: Better for Inflammation, Not Clots
• 3. Lumbrokinase: More Potent, Less Proven for You
• 4. Omega-3s: A Different Job Entirely
• 5. When You Actually Need a Blood Thinner
• 6. So Which Is Better Than Nattokinase? A Goal-by-Goal Guide
• 7. Choosing a Nattokinase That Matches the Research
• 8. Frequently Asked Questions
• 9. Conclusion

1. What Nattokinase Actually Does

"Better" only means something once you name the goal, because nattokinase, serrapeptase, lumbrokinase, and fish oil don't do the same job. Nattokinase is a fibrinolytic enzyme from fermented soybeans that breaks down fibrin — the protein mesh in blood clots — and in animal models it dissolves clots roughly 4 times more effectively than the body's own plasmin, according to a 2018 review in Biomarker Insights. It also inhibits PAI-1 and prompts the release of tissue plasminogen activator, giving it several routes to support the body's own clot-clearing system.

In people, a single oral dose has been shown to measurably enhance thrombolysis and anticoagulation markers in healthy adults (Scientific Reports, 2015). Across that 2023 meta-analysis of six randomized trials and 546 participants, nattokinase lowered systolic blood pressure by about 3.45 mmHg and diastolic by 2.32 mmHg, with no notable adverse events reported.

That record is real but modest. The largest and longest trial — 265 adults taking 2,000 FU daily for 3 years — found no significant difference in carotid-artery thickening versus placebo (0.013 vs 0.011 mm per year), and meaningful cholesterol changes in the research only appeared at far higher doses. So nattokinase sets a solid but unspectacular bar — which is exactly the bar every alternative has to clear.

2. Serrapeptase: Better for Inflammation, Not Clots

Serrapeptase (serratiopeptidase) is the alternative people reach for most, but its evidence points in a different direction. A systematic review in the International Journal of Surgery found that a PubMed search returned 74 studies, 16 clinical trials, and just 9 randomized controlled trials — and most examined inflammation, swelling, and pain, not clots.

Where serrapeptase genuinely shines is localized inflammation: reducing post-surgical swelling and dental or sinus discomfort. Its anti-atherosclerotic and fibrinolytic effects, by contrast, remain largely anecdotal, and the same review called for better-designed long-term trials before drawing cardiovascular conclusions. For systemic blood-flow support, that is a thinner foundation than nattokinase's 6-plus randomized trials.

A practical way to think about it:

• Choose serrapeptase mainly for inflammation or swelling, not clot support
• Expect gastrointestinal upset at higher doses, as with most systemic enzymes
• For a full breakdown, see our nattokinase vs. serrapeptase comparison

3. Lumbrokinase: More Potent, Less Proven for You

Lumbrokinase, an enzyme complex from the earthworm Lumbricus rubellus, is the alternative most often called "stronger" — and per milligram, that may be true. It is highly fibrin-specific, acting mainly where clots already exist, which is why a 2013 multicenter trial in the Chinese Medical Journal added it to standard therapy for stroke survivors.

Over 12 months, that trial reported total vascular events falling from 6.78% to 2.08% and cerebral vascular events from 5.93% to 1.04% versus standard care alone. Those are meaningful numbers — but they come from a narrow, high-risk setting (secondary stroke prevention), usually under medical supervision, not the general "daily circulation support" most shoppers have in mind.

Two cautions keep lumbrokinase from being an automatic upgrade. Its potency isn't standardized across brands — activity units vary widely between manufacturers — and, critically, no head-to-head randomized trial has ever compared standardized lumbrokinase against nattokinase. "More potent in a test tube" is not the same as "better for you," and nattokinase's human evidence base remains substantially larger.

4. Omega-3s: A Different Job Entirely

Fish oil is the most common heart supplement of all, but comparing it to nattokinase is a category error — the two do different jobs. Marine omega-3s (EPA and DHA) mainly lower triglycerides and support vascular function; a major review in the Journal of the American College of Cardiology noted that at typical doses they have no consistent effect on platelet aggregation or coagulation.

In other words, omega-3 is not a fibrinolytic substitute. Its cardiovascular case is also more modest than many assume: an updated meta-analysis of 13 randomized trials and 127,477 participants found only small reductions in some outcomes — roughly 8% for heart attack and coronary death — and no significant benefit for stroke, even though its triglyceride-lowering effect is well established.

So omega-3 wins if your goal is triglycerides or broad heart-healthy nutrition — and because it works on a separate pathway, many people take it alongside nattokinase rather than instead of it. It is a complement more than a competitor.

5. When You Actually Need a Blood Thinner

Here is the part most "alternatives" articles skip: if you have a diagnosed clot, deep vein thrombosis, atrial fibrillation, or a history of stroke, no enzyme supplement is "better" — because none of them substitutes for prescribed anticoagulation. Prescription blood thinners are dosed and monitored for exactly these situations, and the clinical stakes are high.

Nattokinase is generally well tolerated — real-world safety data in patients with vascular disease support its use at typical doses — but it can add to the effect of blood-thinning medications. Published case reports include serious bleeding, such as a cerebellar hemorrhage in a patient combining nattokinase with aspirin. The same caution applies to lumbrokinase, serrapeptase, and high-dose omega-3.

The practical rule is simple: supplements can support healthy circulation in otherwise-healthy adults, but they are not emergency or replacement therapy. If you take warfarin, a DOAC, aspirin, or any antiplatelet drug — or have a bleeding disorder or upcoming surgery — talk to your doctor before adding any of these enzymes.

6. So Which Is Better Than Nattokinase? A Goal-by-Goal Guide

Put the evidence together and "better than nattokinase" resolves into a simple, goal-based answer:

• For evidence-backed fibrinolytic and blood-pressure support: nattokinase leads, with 6-plus randomized trials behind a studied 2,000 FU dose.
• For localized inflammation or swelling: serrapeptase, backed by 9 randomized trials focused on inflammation.
• For a diagnosed clot or stroke risk under medical care: prescription anticoagulants — or, in specific clinical settings, lumbrokinase, which cut total vascular events to 2.08% in one trial.
• For high triglycerides or general heart nutrition: omega-3, which meaningfully lowers triglycerides on a separate pathway.

Seen this way, nattokinase isn't a miracle and it isn't dethroned — it's the best-studied option in a category where every choice is supportive rather than curative. For the specific goal most people have when they search for it — supporting healthy circulation and blood pressure without a prescription — it remains the front-runner, provided you take a dose that matches the research.

7. Choosing a Nattokinase That Matches the Research

If nattokinase fits your goal, the two things that decide whether it works are dose and delivery — and this is where products differ more than labels suggest. The human trials that showed blood-pressure and fibrinolytic benefits used 2,000 FU per day, so BioAbsorb Nattokinase delivers exactly 100 mg / 2,000 FU per capsule — the studied amount, not a rounded-down fraction of it.

Enzymes are also fragile in stomach acid. Rather than a standard enteric coating, BioAbsorb uses a DRcaps delayed-release veggie capsule that protects the enzyme without the phthalates and plasticizers found in some coated capsules, delivering it intact to the small intestine. The formula is intentionally Vitamin K2-free — useful if you already supplement K2 — and comprehensively allergen-free (no gluten, nuts, dairy, egg, fish, or shellfish) and 100% vegetarian.

Every batch is third-party tested for nattokinase activity, heavy metals, and microbial contaminants and made in a Canadian GMP-certified facility. It's a single capsule daily on an empty stomach — a straightforward way to take the dose the research actually used.

8. Frequently Asked Questions

Is nattokinase or serrapeptase better?

It depends on the goal. Serrapeptase has more evidence for inflammation and swelling, while nattokinase has a broader cardiovascular record — 6-plus randomized trials versus serrapeptase's 9 inflammation-focused RCTs. For blood-flow and blood-pressure support, nattokinase is the stronger pick.

Is lumbrokinase stronger than nattokinase?

Per milligram, lumbrokinase is often more potent and more fibrin-specific. But its human evidence is concentrated in stroke settings under medical care, and no trial has directly compared it to nattokinase — so "stronger" doesn't automatically mean "better" for everyday circulation support.

Can I take nattokinase and fish oil together?

Often yes, because they work on different pathways — omega-3 lowers triglycerides while nattokinase supports fibrinolysis. Many people combine them for that reason. Because both can mildly affect bleeding at high intake, check with your doctor first, especially if you take other medications.

Is anything better than nattokinase for blood pressure?

For a natural, non-prescription option, nattokinase has some of the best evidence: a 2023 meta-analysis found about a 3.45 mmHg systolic reduction. Prescription medications lower blood pressure far more, so nattokinase is best seen as supportive — you can read our deeper look at nattokinase and blood pressure, and anyone with hypertension should work with a clinician.

Can nattokinase replace my blood thinner?

No. Nattokinase and similar enzymes are not substitutes for prescribed anticoagulants like warfarin or DOACs, which are dosed and monitored for diagnosed conditions. Combining supplements with blood thinners can raise bleeding risk, so never stop or replace a prescription without medical guidance.

What's the best dose of nattokinase?

The dose used in the landmark human trials is 2,000 FU per day. Much higher doses have been studied for cholesterol, but 2,000 FU is the amount tied to the blood-pressure and fibrinolytic benefits — take it on an empty stomach for best absorption.

9. Conclusion

"What's better than nattokinase" has no single answer — serrapeptase wins for inflammation, omega-3 for triglycerides, and prescription anticoagulants for diagnosed clots — but for evidence-backed fibrinolytic and blood-pressure support, nattokinase's 6-plus randomized trials keep it in front. The key is taking the dose the research used: 2,000 FU per day. If that's your goal, explore BioAbsorb Nattokinase (100 mg / 2,000 FU) and talk with your healthcare provider about whether it fits your plan.

Research References

1. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertension Research, Vol. 31 (2008). A double-blind, placebo-controlled trial in which 2,000 FU/day for 8 weeks reduced systolic blood pressure by a net 5.55 mmHg in adults with pre- or stage-1 hypertension.
2. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in Cardiovascular Medicine, Vol. 24 (2023). Pooled six RCTs (546 participants) and found significant reductions in systolic (−3.45 mmHg) and diastolic (−2.32 mmHg) blood pressure with no notable adverse events.
3. Nattokinase Atherothrombotic Prevention Study: A Randomized Controlled Trial. Clinical Hemorheology and Microcirculation, Vol. 78 (2021). The largest and longest nattokinase RCT (265 adults, 3 years) found no significant difference in carotid intima-media thickness progression versus placebo.
4. Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor. Integrated Blood Pressure Control, Vol. 9 (2016). A North American multicenter RCT reported reduced blood pressure and a 15% reduction in von Willebrand factor after 2,000 FU/day for 8 weeks.
5. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Scientific Reports, Vol. 5 (2015). Demonstrated that a single oral dose measurably enhanced markers of thrombolysis and anticoagulation in healthy adults.
6. Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases. Biomarker Insights, Vol. 13 (2018). A review summarizing nattokinase's fibrinolytic, antihypertensive, and antiplatelet mechanisms, including its direct hydrolysis of fibrin and inhibition of PAI-1.
7. Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases. Nutrients, Vol. 13 (2021). Real-world data supporting the safety of nattokinase at typical supplemental doses in patients with vascular disease.
8. Serratiopeptidase: A systematic review of the existing evidence. International Journal of Surgery (2013). Found limited high-quality evidence (9 RCTs), mostly supporting anti-inflammatory and anti-edemic use, with anti-atherosclerotic effects described as anecdotal.
9. Oral fibrinogen-depleting agent lumbrokinase for secondary ischemic stroke prevention. Chinese Medical Journal, Vol. 126 (2013). A multicenter RCT in which lumbrokinase added to standard care over 12 months reduced total and cerebral vascular events versus standard care alone.
10. Omega-3 Fatty Acids and Cardiovascular Disease: Effects on Risk Factors, Molecular Pathways, and Clinical Events. Journal of the American College of Cardiology (2011). A comprehensive review noting omega-3s lower triglycerides but have no consistent effect on platelet aggregation or coagulation at typical doses.
11. Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127,477 Participants. Journal of the American Heart Association, Vol. 8 (2019). Found small but statistically significant reductions in several cardiovascular outcomes (about 8% for myocardial infarction and coronary heart disease death), with risk reduction increasing with dose, but no significant benefit for stroke.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.